Inherited cancer susceptibility syndromes in paediatric practice

Journal of Paediatrics and Child Health

Volumn 43, Issue 4, 2007, Pages 219-229

  Field, Michael ^a,b   Shanley, Susan ^a,c   Kirk, Judy ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Genetic screening; Hereditary; Molecular diagnostic testing; Neoplastic syndromes; Paediatric

Indexed keywords

APC PROTEIN; BETA CATENIN; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA PROTEIN; VON HIPPEL LINDAU PROTEIN;

ADENOMATOUS POLYP; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CHILDHOOD CANCER; CHROMOSOME DELETION; CLEAR CELL CARCINOMA; CLINICAL EXAMINATION; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; FAMILIAL CANCER; GASTRINOMA; GENE DELETION; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HEMANGIOBLASTOMA; HUMAN; HYPERPARATHYROIDISM; HYPOPHYSIS ADENOMA; INSULINOMA; INTESTINE CANCER; JUVENILE POLYP; KIDNEY CARCINOMA; KIDNEY CYST; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; MUTATIONAL ANALYSIS; NEPHROBLASTOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CYST; PEUTZ JEHGERS SYNDROME; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTO ONCOGENE; RADIODIAGNOSIS; RETINOBLASTOMA; REVIEW; RISK ASSESSMENT; SIGMOIDOSCOPY; SIPPLE SYNDROME; SYNDROME; THYROID MEDULLARY CARCINOMA; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; NEOPLASMS; PEDIATRICS;

EID: 34147123158     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2007.01027.x     Document Type: Review

References (71)

1. Knudson AG. Mutation and cancer - statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1971; 68: 820-3.
2. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J. Clin. Oncol. 1996; 14: 1730-6.
3. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol. 2003; 21: 2397-406.
4. Moll AC, Kuik DJ, Bouter LM et al. Incidence and survival of retinoblastoma in the Netherlands: a register based study 1862-1995. Br. J. Ophthalmol. 1997; 81: 559-62.
5. Friend SH, Bernards R, Rogelj S et al. A human DNA segment with properties of a gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-6.
6. Musarella M, Gallie B. A simplified scheme for genetic counselling in retinoblastoma. J. Paediatr. Ophthalmol. Stabismus. 1987; 24: 124-5.
7. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br. J. Cancer 1986; 53: 661-71.
8. Wong FL, Boice JD, Abramson DH et al. Cancer incidence after retinoblastoma. JAMA 1997; 278: 1262-7.
9. Lohmann DR, Brandt B, Hopping W, Passarge E, Horsthemke B. The spectrum of RB1 germline mutations in hereditary retinoblastoma. Am. J. Hum. Genet. 1996; 58: 940-9.
10. Richter S, Vandezande K, Chen N et al. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am. J. Hum. Genet. 2003; 72: 253-69.
11. European Molecular Genetics Quality Network. Best Practice Guidelines for Rb1 Gene Testing. Available from http://www.emqn.org/emqn/ BestPractice.html [accessed 31 January 2007].
12. Maher ER, Iselius L, Yates JR et al. Von Hippel-Lindau disease: a genetic study. J. Med. Genet. 1991; 28: 443-7.
13. Maher ER, Yates JRW, Harris R et al. Clinical features and natural history of Von Hippel-Lindau disease. QJM 1990; 77: 1151-63.
14. Schimke RN, Collins DL, Stolle CA.Von Hippel Lindau Syndrome Gene Reviews, 2004. Available from: http://www.genetests.org [accessed 29 January 2007].
15. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumour suppressor gene. Science 1993; 260: 1317-20.
16. Lonser RR, Glenn GM, McClellan W et al. Von Hippel-Lindau disease. Lancet 2003; 361: 2059-67.
17. Madhusudan S, Deplanque G, Baybrooke JP et al. Antiangiogenic therapy for von Hippel-Lindau disease. JAMA 2004; 291: 943-4.
18. Wittebol-Post D, Hes FJ, Lips CJ. The eye in von Hippel-Lindau disease. Long-term follow-up of screening and treatment: recommendations. J. Intern. Med. 1998; 243: 555-61.
19. Richard S, Campello C, Taillandier L, Parker F, Resche F. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J. Intern. Med. 1998; 243: 547-53.
20. Neumann HPH, Zbar B. Renal cysts, renal cancer and von Hippel-Lindau disease. Kidney Int. 1997; 51: 16-26.
21. Wanebo JE, Lonser RR, Glen GM, Oldfield EH. The natural history of central nervous system hemangioblastomas in patients with von Hippel-Lindau disease. J. Neurosurg. 2003; 98: 106-16.
22. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. Von Hippel-Lindau disease-genetic, clinical and imaging features. Radiology 1995; 194: 629-42.
23. Maher EA, Zbar B. Genetic predisposition to renal cancer. Genetic Predisposition to Cancer. In: Eeles R, Easton DF, Ponder BAJ, Eng C, eds. London: Arnold, 2004; 132-40.
24. Biggs M. Von Hippel-Lindau disease: a guide to early recognition. Mod. Med. Aust. 1998; 41: 26-30.
25. Bussey HJR. Familial Polyposis Coli. Family Studies, Histopathology, Differential Diagnosis and Results of Treatment. Baltimore: the John Hopkins University Press, 1975.
26. Groden J, Thliveris A, Samowitz W et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589-600.
27. Fearnhead N, Britton M, Bodmer W. The ABC APC. Hum. Mol. Genet. 2001; 10: 721-33.
28. Lipton L, Tomlinson I. The multiple colorectal adenoma phenotype and MYH, a base excision repair gene. Clin. Gastroenterol. Hepatol. 2004; 2: 633-8.
29. Jenkins MA, Croitoru ME, Monga N et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol. Biomarkers. Prev. 2006; 15: 312-14.
30. Jarvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival. Gut 1992; 33: 357-60.
31. Hemminski A, Markie D, Tomlinson I et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391: 184-7.
32. Scott RJ, Crooks R, Meldrum CJ et al. Mutation analysis of the STK11/LKB1 gene and clinical characteristics of an Australian series of Peutz-Jeghers syndrome patients. Clin. Genet. 2002; 62: 282-7.
33. Boardman LA, Thibodeau SN, Schaid DJ et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann. Intern. Med. 1998; 128: 896-9.
34. Sweet K, Willis J, Zhou XP et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005; 294: 2465-73.
35. Celebi JT, Tsou HC, Chen FF et al. Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN. J. Med. Genet. 1999; 36: 360-4.
36. Chandrasekharappa SC, Guru SC, Manickam P et al. Position cloning of the gene for multiple endocrine neoplasia-type1. Science 1997; 276: 404-7.
37. Mulligan LM, Kwok JBJ, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-60.
38. Brandi ML, Gagel RF, Angeli A et al. Guideline for diagnosis and therapy of MEN type 1 and MEN type 2. J. Clin. Endocrinol. Metab. 2001; 86: 5658-71.
39. Learoyd DL, Delbridge LW, Robinson BG. Multiple endocrine neoplasia. Aust. NZ J. Med. 2000; 30: 675-82.
40. Agarwal SK, Kester MB, Debelenko LV et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum. Mol. Genet. 1997; 7: 1169-75.
41. Neumann HP, Bausch B, McWhinney SR et al. Germline mutations in non syndromic pheochromocytoma. N. Engl. J. Med. 2002; 346: 1459-66.
42. Li FP, Fraumeni JF. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J. Natl. Cancer Inst. 1969; 43: 1365-73.
43. Malkin D, Li FP, Strong LC et al. Germline p53 mutations in a familial syndrome of breast cancer sarcomas and other neoplasms. Science 1990; 250: 1233-8.
44. Birch JM, Alston RD, McNally RJ et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001; 20: 4621-8.
45. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomarkers Prev. 2001; 10: 83-7.
46. Le Bihan C, Moutou C, Brugieres L, Feunteun J, Bonaiti-Pellie C. ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet. Epidemiol. 1995; 12: 13-25.
47. Li FP, Fraumeni JF, Mulvihill JJ et al. A cancer family syndrome in twentyfour kindreds. Cancer Res. 1988; 48: 5358-62.
48. Varley JM, McGown G, Thorncroft M et al. Germline mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 1997; 57: 3245-52.
49. Birch JM. Li-Fraumeni syndrome. Eur. J. Cancer 1994; 30: 1935-41.
50. Chompret A, Abel A, Stoppa-Lyonnet D et al. Sensitivity and predictive value for p53 germline mutation screening. J. Med. Genet. 2001; 38: 43-7.
51. Eales RA. Germline mutations in the TP53 gene. Cancer Surv. 1995; 25: 101-23.
52. Ruteshouser EC, Huff V. Familial wilms tumour. Am. J. Med. Genet. C. Semin. Med. Genet. 2004; 129: 29-34.
53. Ritchey ML, Shamberger RC, Hamilton T, Haase G, Argani P, Peterson S. Fate of bilateral renal lesions missed on preoperative imaging reported from the National Wilms Tumour Study Group. J. Urol. 2005; 87: 241-4.
54. Merks J, Caron HN, Hennekam RC. High incidence of malformation syndromes in a series of 1073 children with cancer. Am. J. Med. Genet. A. 2005; 134: 132-43.
55. McNeil DE, Brown M, Ching A, De Baum MR. Screening for Wilms tumor and hepatoblastoma in children with Beckwith-Wiedemann syndromes: a cost-effective model. Med. Pediatr. Oncol. 2001; 37: 349-56.
56. Gutmann DH, Aylsworth A, Carey JC et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278: 51-7.
57. McGaughran J, Harris D, Donnai D et al. A clinical study of type 1 neurofibromatosis in north west England. J. Med. Genet. 1999; 36: 197-203.
58. Brodeur GM. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. NEJM 1994; 330: 637-8.
59. Huson SM, Clark P, Compston DA, Harper PS. A genetic study of von recklinghausen's neurofibromatosis in South East Wales: prevalence, fitness, mutation rate and effect of parental transmission on severity. J. Med. Genet. 1989; 206: 704-11.
60. Evans DG, Huson SM, Donnai D et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. Prevelance, mutation rate, fitness and confirmation of maternal transmission effect on severity. J. Med. Genet. 1992; 29: 841-6.
61. Trofatter JA, MacCollin MM, Rutter JL et al. A novel moesin-, ezrin, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791-800.
62. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann. Intern. Med. 1990; 113: 39-52.
63. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2). clinical characteristics of 63 affected individuals and clinical evidence of heterogeneity. Am. J. Hum. Genet. 1996; 52: 450-61.
64. Moyhuddin A, Baser ME, Watson C et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J. Med. Genet. 2003; 40: 109-14.
65. Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch. Dis. Child. 1999; 81: 496-9.
66. Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J. Population-based analysis of sporadic and type 2 neurofibromatosisassociated meningiomas and schwannomas. Neurology 2000; 54: 71-6.
67. Slattery WH, Brackmann DE, Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am. J. Otol. 1998; 98: 534-8.
68. Evans DG, Newton V, Neary W et al. Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2). J. Med. Genet. 2000; 37: 944-7.
69. Evans DG, Sainio M, Baser M et al. Neurofibromatosis type 2. J. Med. Genet. 2000; 37: 897-904.
70. MacCollin M. Neurofibromatosis 2: clinical aspects. In: Friedmann JM et al., eds. Neurofibromatosis. Phenotype, Natural History and Pathogenesis, 3rd edn. Baltimore: Johns Hopkins University Press, 1999; 299-326.
71. MacCollin M, Ramesh V, Jacoby LB et al. Mutational analysis of patients with neurofibromatosis 2. Am. J. Hum. Genet. 1994; 55: 314-20.